DNA‐based vaccination for the treatment of food allergy
Authors:
Abstract
At present, avoidance is the only therapeutic option available for individuals with food allergies. However, studies suggest that DNA‐based vaccination might be an effective therapeutic option for the reversal of allergic hypersensitivities, including allergies to foods. Because severe anaphylactic reactions represent a life‐threatening risk for individuals with food allergies, we and others have evaluated the effectiveness of DNA‐based vaccination for the prevention of anaphylactic hypersensitivity in murine models. Our investigations demonstrated that primary gene and protein/immunostimulatory sequence oligodeoxynucleotide (ISS‐ODN) vaccination of subsequently Th2‐sensitized mice reduced the risk of death after anaphylactic challenge, significantly. In addition, gene and protein/ISS‐ODN vaccination reduced post challenge plasma histamine levels. Analysis of the immune profiles of mice receiving DNA‐based vaccines showed that both gene and protein/ISS‐ODN vaccination effectively prevented the development of Th2‐biased immune profiles after sensitization. In contrast, vaccination with protein alone, the experimental equivalent of the traditional protein‐based immunotherapy (IT) reagents used in clinical practice provided no protection from anaphylaxis, nor did it prevent the development of a Th2‐biased immune profile after allergen sensitization. These studies justify continued optimism in the potential of DNA‐based vaccination for the desensitization of food allergic individuals.Keywords
This publication has 17 references indexed in Scilit:
- DNA-based vaccination reduces the risk of lethal anaphylactic hypersensitivity in miceJournal of Allergy and Clinical Immunology, 2000
- Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicityJournal of Allergy and Clinical Immunology, 2000
- Food allergy. Part 1: Immunopathogenesis and clinical disordersJournal of Allergy and Clinical Immunology, 1999
- Immunostimulatory DNA Is a Potent Mucosal AdjuvantCellular Immunology, 1998
- Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and Fc gammaRIII. Assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE- or IgG1-dependent passive anaphylaxis.Journal of Clinical Investigation, 1997
- Impaired IgG-Dependent Anaphylaxis and Arthus Reaction in FcγRIII (CD16) Deficient MiceImmunity, 1996
- Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization.Proceedings of the National Academy of Sciences, 1996
- Immunoprophylaxis of allergen–induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunizationNature Medicine, 1996
- Active anaphylaxis in IgE-deficient miceNature, 1994
- Fatal and Near-Fatal Anaphylactic Reactions to Food in Children and AdolescentsNew England Journal of Medicine, 1992